Travere Therapeutics Announces Corporate Update and 2026 Strategic Outlook

Travere Therapeutics Reports Record FILSPARI Performance in 4Q 2025, Advances Regulatory and Clinical Milestones Ahead of 2026 Travere Therapeutics a biopharmaceutical company focused on developing and delivering transformative therapies for people living with rare kidney and metabolic diseases, today announced…









